MRI manufacturer Hyperfine, medical device company Liminal Sciences and HealthCor Catalio Acquisition announced that the SEC has declared effective the Form S-4 outlining the three-way business combination.
A meeting of HealthCor shareholders to vote on the deal is set for Dec. 21.
If approved, upon closing the new company will be named Hyperfine and list on the Nasdaq under HYPR.
Announced in July, the transaction would provide the combined companies with approximately $375 million. The merged company’s estimated cash balance will consist of $207 million from the SPAC’s trust, $126 million from a PIPE, and $66 million from the balance sheets of Hyperfine and Liminal, less $24 million transaction expenses. Read more.
